Scherer L, Soudant M, Pittion-Vouyovitch S, Debouverie M, et al. Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study. J Neurol 2024 Feb 29. doi: 10.1007/s00415-024-12266.
PMID: 38421420